



Keating Capital Makes Investment in Solazyme

Pre-IPO Investor Backs Solazyme, a Renewable Oil and Bioproducts Producer

August 10, 2010 – Greenwood Village, Colorado – On July 16, 2010, Keating Capital, Inc. (www.KeatingCapital.com) made a \$1 million investment in the Series D Convertible Preferred Stock of Solazyme, Inc. (www.solazyme.com) (“Solazyme”). This investment is Keating Capital’s third portfolio company investment.

Braemar Energy Ventures and new investor, Morgan Stanley, led the \$52 million Series D Preferred Stock round with all major existing investors from previous rounds participating, including Lightspeed Venture Partners, The Roda Group, Harris and Harris Group, VantagePoint Venture Partners and Zygote Ventures. Existing strategic investors CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC, and San-Ei Gen, a major Japanese manufacturer and distributor of food ingredients, also participated.

Founded in 2003 and based in South San Francisco, CA, Solazyme is a renewable oil and green bioproducts company and is considered a leader in the development and commercialization of [algal oil](#) and [bioproducts](#) for the fuels and chemicals, nutritionals and health sciences markets. Solazyme’s unique, proprietary technology allows algae, when fed sugars and plant byproducts, to produce oil and biomaterials in industrial fermentation facilities.

Solazyme has been recognized with numerous awards such as [Biofuels Digest’s #1 of the 50 Hottest Companies in Bioenergy for 2009-2010](#), [Red Herring Global 100](#) and the [World Biofuels Markets’ #1 Sustainable Biofuels Technology Award for 2010](#).

About Keating Capital, Inc.

Keating Capital (www.KeatingCapital.com) is a business development company that specializes in making pre-IPO investments in innovative, high growth private companies that are committed to and capable of becoming public. Keating Capital provides individual investors with the ability to participate in a **unique fund that invests in a private company’s late stage, pre-IPO financing round** — an opportunity that has historically been reserved for institutional investors only.